SG11201705915VA - Therapeutic agent for ischemic diseases - Google Patents
Therapeutic agent for ischemic diseasesInfo
- Publication number
- SG11201705915VA SG11201705915VA SG11201705915VA SG11201705915VA SG11201705915VA SG 11201705915V A SG11201705915V A SG 11201705915VA SG 11201705915V A SG11201705915V A SG 11201705915VA SG 11201705915V A SG11201705915V A SG 11201705915VA SG 11201705915V A SG11201705915V A SG 11201705915VA
- Authority
- SG
- Singapore
- Prior art keywords
- therapeutic agent
- ischemic diseases
- ischemic
- diseases
- therapeutic
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 208000023589 ischemic disease Diseases 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/30—Animals modified by surgical methods
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/101—Plasmid DNA for bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/50—Fibroblast growth factors [FGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015007760 | 2015-01-19 | ||
PCT/JP2016/051293 WO2016117508A1 (en) | 2015-01-19 | 2016-01-18 | Therapeutic agent for ischemic diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201705915VA true SG11201705915VA (en) | 2017-08-30 |
Family
ID=56417053
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201705915VA SG11201705915VA (en) | 2015-01-19 | 2016-01-18 | Therapeutic agent for ischemic diseases |
Country Status (8)
Country | Link |
---|---|
US (1) | US10993972B2 (en) |
EP (1) | EP3249043B1 (en) |
JP (1) | JP6258526B2 (en) |
KR (1) | KR101892722B1 (en) |
CN (1) | CN107208108B (en) |
CA (1) | CA2974333C (en) |
SG (1) | SG11201705915VA (en) |
WO (1) | WO2016117508A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018062225A1 (en) * | 2016-09-28 | 2018-04-05 | 株式会社アネロファーマ・サイエンス | Gene expression promotor for bifidobacterium genus bacteria |
CN108611367B (en) * | 2018-04-24 | 2019-11-19 | 北京诺思兰德生物技术股份有限公司 | The gene therapy recombinant vector that one kind is mediated by plasmid vector |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6416754B1 (en) | 1994-03-03 | 2002-07-09 | The Board Of Trustees Of The Leland Stanford Junior University | Anaerobe targeted enzyme-mediated prodrug therapy |
US6984513B2 (en) | 1994-03-03 | 2006-01-10 | The Board Of Trustees Of The Leland Stanford Junior University | Anaerobe targeted enzyme-mediated prodrug therapy |
JP3642755B2 (en) | 2000-09-21 | 2005-04-27 | 純 天野 | Drugs for gene therapy using anaerobic bacteria |
US20020054865A1 (en) | 2000-09-21 | 2002-05-09 | Minoru Fujimori | Anaerobic bacterium as a drug for cancer gene therapy |
JP3998171B2 (en) | 2001-06-15 | 2007-10-24 | 独立行政法人科学技術振興機構 | Method for discriminating signal peptide and computer program therefor |
PT2468861E (en) | 2006-05-24 | 2014-12-05 | Anaeropharma Science Inc | Method of constructing gene transport support |
EP2274422B1 (en) * | 2008-04-17 | 2017-03-15 | Anaeropharma Science, Inc. | Expression vector |
US9730968B2 (en) * | 2008-04-17 | 2017-08-15 | Anaeropharma Science, Inc. | Therapeutic agent for ischemic diseases |
EP2910636B1 (en) * | 2010-01-29 | 2018-01-17 | Anaeropharma Science, Inc. | Transformation plasmid |
CN103958680A (en) * | 2011-07-13 | 2014-07-30 | 阿内罗药物科学株式会社 | Therapeutic agent for ischemic diseases |
EP2873726B1 (en) * | 2012-07-13 | 2018-09-05 | Teikyo Heisei University | Antitumor agent, marker for tumor detection, and oral vaccine agent |
SG11201609032WA (en) | 2014-05-01 | 2016-12-29 | Anaeropharma Science Inc | Heterogeneous polypeptide expression cassette |
-
2016
- 2016-01-18 SG SG11201705915VA patent/SG11201705915VA/en unknown
- 2016-01-18 KR KR1020177023311A patent/KR101892722B1/en active IP Right Grant
- 2016-01-18 JP JP2016570626A patent/JP6258526B2/en active Active
- 2016-01-18 US US15/544,565 patent/US10993972B2/en active Active
- 2016-01-18 CN CN201680006161.9A patent/CN107208108B/en active Active
- 2016-01-18 EP EP16740115.7A patent/EP3249043B1/en active Active
- 2016-01-18 WO PCT/JP2016/051293 patent/WO2016117508A1/en active Application Filing
- 2016-01-18 CA CA2974333A patent/CA2974333C/en active Active
Also Published As
Publication number | Publication date |
---|---|
JPWO2016117508A1 (en) | 2017-12-07 |
EP3249043A1 (en) | 2017-11-29 |
US20180360893A1 (en) | 2018-12-20 |
CN107208108A (en) | 2017-09-26 |
KR101892722B1 (en) | 2018-08-28 |
CA2974333C (en) | 2018-09-25 |
WO2016117508A1 (en) | 2016-07-28 |
JP6258526B2 (en) | 2018-01-10 |
EP3249043A4 (en) | 2018-08-29 |
KR20170105102A (en) | 2017-09-18 |
CN107208108B (en) | 2019-05-17 |
CA2974333A1 (en) | 2016-07-28 |
EP3249043B1 (en) | 2019-11-06 |
US10993972B2 (en) | 2021-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1256383A1 (en) | Therapeutic agents | |
IL250685A0 (en) | Cytotoxicity-inducing therapeutic agent | |
GB201509893D0 (en) | Therapeutic agents | |
IL258997B (en) | Honey-cannabinoid therapeutic composition | |
GB201517263D0 (en) | Therapeutic agents | |
GB201410816D0 (en) | Therapeutic agents | |
GB201603104D0 (en) | Therapeutic agents | |
HK1258727A1 (en) | Therapeutic compounds | |
GB201502412D0 (en) | Therapeutic use | |
HK1245639A1 (en) | Therapeutic agent for fibrosis | |
GB201410815D0 (en) | Therapeutic agents | |
GB201410817D0 (en) | Therapeutic agents | |
GB201509885D0 (en) | Therapeutic agents | |
GB201509888D0 (en) | Therapeutic agents | |
GB201617339D0 (en) | Therapeutic compounds | |
GB201616839D0 (en) | Therapeutic compounds | |
GB201513299D0 (en) | Therapeutic agents | |
SG11201705915VA (en) | Therapeutic agent for ischemic diseases | |
GB201521767D0 (en) | Therapeutic agents | |
IL263821A (en) | Therapeutic compounds | |
EP3508214A4 (en) | Therapeutic agent for ischemic diseases | |
GB201517264D0 (en) | Therapeutic agents | |
GB201506786D0 (en) | Therapeutic use | |
GB201702921D0 (en) | Therapeutic agent | |
GB201620948D0 (en) | Therapeutic agents |